Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579301 | 0.93 | NPC1 (0.55) | CA2NPC1POLBRAB9AHSD17B10 | |
| SCHEMBL7928047 | 0.92 | PDE4A (0.52) | SIGMAR1MAPT | |
| SCHEMBL7038976 | 0.91 | MAPT (0.49) | NPSR1NPC1POLBRAB9AMAPT | |
| SCHEMBL7997662 | 0.88 | TUBB1 (0.55) | CA2SIGMAR1TMEM97NPC1POLB | |
| SCHEMBL3972900 | 0.86 | L3MBTL1 (0.54) | CA2NPC1POLBRAB9AMAPT | |
| SCHEMBL579348 | 0.85 | NPC1 (0.54) | CA2NPC1POLBRAB9AMAPT | |
| SCHEMBL29521379 | 0.85 | REN (0.48) | CA2NPC1POLBRAB9AMAPT | |
| SCHEMBL2810242 | 0.85 | REN (0.48) | CA2NPC1POLBRAB9AMAPT | |
| SCHEMBL20230392 | 0.84 | L3MBTL1 (0.47) | CA2SIGMAR1EBPTMEM97NPC1 | |
| Alcohol SCHEMBL8946306 | 0.83 | CA2 (0.63) | CA2NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112262-B1 | SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO | INFLAZYME PHARM LTD (CA) | 2004-08-04 | — | — | EP | disclosed |
| US-6770658-B2 | FOR TREATMENT/PREVENTION OF INFLAMMATION; FOR MODULATING INTRACELLULAR CYCLIC ADENOSINE 5'-MONOPHOSPHATE LEVELS (CAMP) | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-08-03 | — | — | US | disclosed |
| US-20030186943-A1 | Substituted gamma-phenyl-delta-lactams and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6458829-B1 | OR LACTAMS THEY MAY BE FORMULATED INTO PHARMACEUTICAL COMPOSITIONS, AND/OR USED IN THE TREATMENT OR PREVENTION OF INFLAMMATION | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2002-10-01 | — | — | US | disclosed |
| EP-1112262-A1 | SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO | Inflazyme Pharmaceuticals, Ltd. (CA) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014083-A1 | SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186943-A1 | Substituted gamma-phenyl-delta-lactams and uses related thereto | DDO, GLA, PIGO | NPSR1 3593/4885CA2 3977/4885SIGMAR1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.